Silodosina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Silodosina" in Italian language version.

refsWebsite

Global rank Italian rank

16nih.gov

4^th place

9^th place

10oadoi.org

799^th place

22^nd place

10doi.org

2^nd place

7^th place

doi.org

dx.doi.org

M. Yoshida, Y. Homma; K. Kawabe, Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia., in Expert Opin Investig Drugs, vol. 16, n. 12, Dic 2007, pp. 1955-65, DOI:10.1517/13543784.16.12.1955, PMID 18042003.
A. Nagai, R. Hara; T. Yokoyama; Y. Jo; T. Fujii; Y. Miyaji, Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography., in Int J Urol, vol. 15, n. 10, Ott 2008, pp. 915-918, DOI:10.1111/j.1442-2042.2008.02136.x, PMID 18721206.
K. Kobayashi, N. Masumori; S. Hisasue; R. Kato; K. Hashimoto; N. Itoh; T. Tsukamoto, Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers., in J Sex Med, vol. 5, n. 9, Set 2008, pp. 2185-90, DOI:10.1111/j.1743-6109.2008.00779.x, PMID 18399947.
MA. Cantrell, HR. Bream-Rouwenhorst; P. Hemerson; JS. Magera, Silodosin for benign prostatic hyperplasia., in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 302-10, DOI:10.1345/aph.1M320, PMID 20071497.
M. Rossi, T. Roumeguère, Silodosin in the treatment of benign prostatic hyperplasia., in Drug Des Devel Ther, vol. 4, 2010, pp. 291-7, DOI:10.2147/DDDT.S10428, PMID 21116335.
MP. Curran, Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report., in Drugs Aging, vol. 28, n. 10, Ott 2011, pp. 843-5, DOI:10.2165/11207800-000000000-00000, PMID 21970311.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia., in Clin Interv Aging, vol. 6, 2011, pp. 161-72, DOI:10.2147/CIA.S13803, PMID 21753871.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms., in Int J Urol, vol. 19, n. 4, aprile 2012, pp. 306-16, DOI:10.1111/j.1442-2042.2011.02957.x, PMID 22251148.
Y. Homma, K. Kawabe; M. Takeda; M. Yoshida, Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia., in Urology, vol. 76, n. 6, Dic 2010, pp. 1446-50, DOI:10.1016/j.urology.2010.03.015, PMID 20472263.
F. Shimizu, M. Taguri; Y. Harada; Y. Matsuyama; K. Sase; M. Fujime, Impact of dry ejaculation caused by highly selective alpha1A-blocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men., in J Sex Med, vol. 7, n. 3, marzo 2010, pp. 1277-83, DOI:10.1111/j.1743-6109.2009.01663.x, PMID 20102447.

nih.gov

ncbi.nlm.nih.gov

K. Akiyama, M. Hora; S. Tatemichi; N. Masuda; S. Nakamura; R. Yamagishi; M. Kitazawa, KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model., in J Pharmacol Exp Ther, vol. 291, n. 1, Ott 1999, pp. 81-91, PMID 10490890.
S. Yamada, T. Okura; R. Kimura, In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues., in J Pharmacol Exp Ther, vol. 296, n. 1, gennaio 2001, pp. 160-7, PMID 11123376.
M. Yoshida, Y. Homma; K. Kawabe, Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia., in Expert Opin Investig Drugs, vol. 16, n. 12, Dic 2007, pp. 1955-65, DOI:10.1517/13543784.16.12.1955, PMID 18042003.
A. Nagai, R. Hara; T. Yokoyama; Y. Jo; T. Fujii; Y. Miyaji, Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography., in Int J Urol, vol. 15, n. 10, Ott 2008, pp. 915-918, DOI:10.1111/j.1442-2042.2008.02136.x, PMID 18721206.
R. Furuya, N. Masumori; S. Furuya; H. Ogura; M. Mutoh; K. Kobayashi; S. Hisasue; T. Tsukamoto, [Investigation of adverse events and the continuance rate of silodosin in all patients who received silodosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia]., in Nihon Hinyokika Gakkai Zasshi, vol. 101, n. 1, gennaio 2010, pp. 13-7, PMID 20158073.
K. Kobayashi, N. Masumori; S. Hisasue; R. Kato; K. Hashimoto; N. Itoh; T. Tsukamoto, Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers., in J Sex Med, vol. 5, n. 9, Set 2008, pp. 2185-90, DOI:10.1111/j.1743-6109.2008.00779.x, PMID 18399947.
Y. Matsubara, T. Kanazawa; Y. Kojima; Y. Abe; K. Kobayashi; H. Kanbe; H. Harada; Y. Momose; S. Terakado; Y. Adachi; I. Midgley, [Pharmacokinetics and disposition of silodosin (KMD-3213)]., in Yakugaku Zasshi, 126 Spec no., marzo 2006, pp. 237-45, PMID 16518089.
T. Shimizu, I. Miyashita; Y. Matsubara; M. Ikeda; M. Yamaguchi, [Pharmacokinetic profile of silodosin in clinical practice]., in Yakugaku Zasshi, 126 Spec no., marzo 2006, pp. 257-63, PMID 16518091.
MA. Cantrell, HR. Bream-Rouwenhorst; P. Hemerson; JS. Magera, Silodosin for benign prostatic hyperplasia., in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 302-10, DOI:10.1345/aph.1M320, PMID 20071497.
M. Rossi, T. Roumeguère, Silodosin in the treatment of benign prostatic hyperplasia., in Drug Des Devel Ther, vol. 4, 2010, pp. 291-7, DOI:10.2147/DDDT.S10428, PMID 21116335.
MP. Curran, Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report., in Drugs Aging, vol. 28, n. 10, Ott 2011, pp. 843-5, DOI:10.2165/11207800-000000000-00000, PMID 21970311.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia., in Clin Interv Aging, vol. 6, 2011, pp. 161-72, DOI:10.2147/CIA.S13803, PMID 21753871.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms., in Int J Urol, vol. 19, n. 4, aprile 2012, pp. 306-16, DOI:10.1111/j.1442-2042.2011.02957.x, PMID 22251148.
Y. Homma, K. Kawabe; M. Takeda; M. Yoshida, Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia., in Urology, vol. 76, n. 6, Dic 2010, pp. 1446-50, DOI:10.1016/j.urology.2010.03.015, PMID 20472263.
F. Shimizu, M. Taguri; Y. Harada; Y. Matsuyama; K. Sase; M. Fujime, Impact of dry ejaculation caused by highly selective alpha1A-blocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men., in J Sex Med, vol. 7, n. 3, marzo 2010, pp. 1277-83, DOI:10.1111/j.1743-6109.2009.01663.x, PMID 20102447.
Silodosin: erectile and ejaculatory disorders., in Prescrire Int, vol. 21, n. 127, Mag 2012, p. 129, PMID 22844684.

oadoi.org

M. Yoshida, Y. Homma; K. Kawabe, Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia., in Expert Opin Investig Drugs, vol. 16, n. 12, Dic 2007, pp. 1955-65, DOI:10.1517/13543784.16.12.1955, PMID 18042003.
A. Nagai, R. Hara; T. Yokoyama; Y. Jo; T. Fujii; Y. Miyaji, Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography., in Int J Urol, vol. 15, n. 10, Ott 2008, pp. 915-918, DOI:10.1111/j.1442-2042.2008.02136.x, PMID 18721206.
K. Kobayashi, N. Masumori; S. Hisasue; R. Kato; K. Hashimoto; N. Itoh; T. Tsukamoto, Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers., in J Sex Med, vol. 5, n. 9, Set 2008, pp. 2185-90, DOI:10.1111/j.1743-6109.2008.00779.x, PMID 18399947.
MA. Cantrell, HR. Bream-Rouwenhorst; P. Hemerson; JS. Magera, Silodosin for benign prostatic hyperplasia., in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 302-10, DOI:10.1345/aph.1M320, PMID 20071497.
M. Rossi, T. Roumeguère, Silodosin in the treatment of benign prostatic hyperplasia., in Drug Des Devel Ther, vol. 4, 2010, pp. 291-7, DOI:10.2147/DDDT.S10428, PMID 21116335.
MP. Curran, Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report., in Drugs Aging, vol. 28, n. 10, Ott 2011, pp. 843-5, DOI:10.2165/11207800-000000000-00000, PMID 21970311.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia., in Clin Interv Aging, vol. 6, 2011, pp. 161-72, DOI:10.2147/CIA.S13803, PMID 21753871.
M. Yoshida, J. Kudoh; Y. Homma; K. Kawabe, New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms., in Int J Urol, vol. 19, n. 4, aprile 2012, pp. 306-16, DOI:10.1111/j.1442-2042.2011.02957.x, PMID 22251148.
Y. Homma, K. Kawabe; M. Takeda; M. Yoshida, Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia., in Urology, vol. 76, n. 6, Dic 2010, pp. 1446-50, DOI:10.1016/j.urology.2010.03.015, PMID 20472263.
F. Shimizu, M. Taguri; Y. Harada; Y. Matsuyama; K. Sase; M. Fujime, Impact of dry ejaculation caused by highly selective alpha1A-blocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men., in J Sex Med, vol. 7, n. 3, marzo 2010, pp. 1277-83, DOI:10.1111/j.1743-6109.2009.01663.x, PMID 20102447.